The purpose of a new study published in The Journal of Pediatrics was to determine whether trace amounts of ethylene glycol (EG), diethylene glycol (DEG), or triethylene glycol (TEG) in PEG 3350 are associated with increased blood levels of EG, DEG, or TEG in children receiving daily PEG 3350 therapy. The study entailed collection of blood samples from nine children, between 6-12 years of age, who were being treated for constipation with PEG 3350, before and every 30 minutes for three hours after receiving 17 g of PEG 3350. Additionally, PEG 3350, tap water, and blood samples from 18 age- and sex-matched controls were analyzed. The findings revealed that baseline blood levels of EG and TEG did not differ between the control and the treated groups. DEG levels were found to be lower in the PEG 3350 group. After the PEG 3350 dose, levels of EG and TEG peaked at 90 minutes at 1032.81 ng/mL and 35.17 ng/mL, respectively. Whereas, DEG levels did not significantly change. Standard 17-g doses of PEG 3350 in 8 oz (237 mL) of water resulted in concentrations (mean ± SD) of EG, DEG, and TEG of 1.32 ± 0.23 µg/mL, 0.18 ± 0.03 µg/mL, and 0.12 ± 0.01 µg/mL, respectively. Meanwhile, EG, DEG, and TEG levels in public water supply were 0.07 µg/mL, 0.21 µg/mL, and 0.02 µg/mL, respectively. Hence, it was concluded that daily PEG 3350 therapy in children was not associated with sustained elevation of EG, DEG, or TEG blood levels over levels in matched controls. It was stated that although EG and TEG levels increased after a standard dose of PEG 3350, their peak values remained well below toxic levels.